Abstract
Background: Tangles are deposits of hyperphosphorylated tau, which are found in multiple neurodegenerative disorders that are referred to as tauopathies, of which Alzheimer's disease (AD) is the most common. Tauopathies are clinically characterized by dementia and share common cortical lesions composed of aggregates of the protein tau.
Objective: In this study, we explored the therapeutic potential of tolfenamic acid (TA), in modifying disease processes in a transgenic animal model that carries the human tau gene (hTau).
Methods: Behavioral tests, Western blotting and Immunohistochemical analysis were used to demonstrate the efficacy of TA.
Results: Treatment of TA improved improving spatial learning deficits and memory impairments in young and aged hTau mice. Western blot analysis of the hTau protein revealed reductions in total tau as well as in sitespecific hyperphosphorylation of tau in response to TA administration. Immunohistochemical analysis for phosphorylated tau protein revealed reduced staining in the frontal cortex, hippocampus, and striatum in animals treated with TA.
Conclusion: TA holds the potential as a disease-modifying agent for the treatment of tauopathies including AD.
Keywords: Alzheimer's disease, tolfenamic acid, hTau mouse model, tauopathy, microtubule-associated protein Tau (MAPT), dementia.
Current Alzheimer Research
Title:Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy
Volume: 15 Issue: 7
Author(s): Joanna K. Chang, Allison Leso, Gehad M. Subaiea, Asma Lahouel, Anwar Masoud, Foqia Mushtaq, Reem Deeb, Aseel Eid, Miriam Dash , Syed W. Bihaqi and Nasser H. Zawia*
Affiliation:
- Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI,United States
Keywords: Alzheimer's disease, tolfenamic acid, hTau mouse model, tauopathy, microtubule-associated protein Tau (MAPT), dementia.
Abstract: Background: Tangles are deposits of hyperphosphorylated tau, which are found in multiple neurodegenerative disorders that are referred to as tauopathies, of which Alzheimer's disease (AD) is the most common. Tauopathies are clinically characterized by dementia and share common cortical lesions composed of aggregates of the protein tau.
Objective: In this study, we explored the therapeutic potential of tolfenamic acid (TA), in modifying disease processes in a transgenic animal model that carries the human tau gene (hTau).
Methods: Behavioral tests, Western blotting and Immunohistochemical analysis were used to demonstrate the efficacy of TA.
Results: Treatment of TA improved improving spatial learning deficits and memory impairments in young and aged hTau mice. Western blot analysis of the hTau protein revealed reductions in total tau as well as in sitespecific hyperphosphorylation of tau in response to TA administration. Immunohistochemical analysis for phosphorylated tau protein revealed reduced staining in the frontal cortex, hippocampus, and striatum in animals treated with TA.
Conclusion: TA holds the potential as a disease-modifying agent for the treatment of tauopathies including AD.
Export Options
About this article
Cite this article as:
Chang K. Joanna, Leso Allison, Subaiea M. Gehad, Lahouel Asma, Masoud Anwar, Mushtaq Foqia, Deeb Reem, Eid Aseel, Dash Miriam, Bihaqi W. Syed and Zawia H. Nasser*, Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy, Current Alzheimer Research 2018; 15(7) . https://dx.doi.org/10.2174/1567205015666180119104036
| DOI https://dx.doi.org/10.2174/1567205015666180119104036 |
Print ISSN 1567-2050 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Frailty Among Alzheimer’s Disease Patients
CNS & Neurological Disorders - Drug Targets Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Association of Amyloid Burden, Brain Atrophy and Memory Deficits in Aged Apolipoprotein ε4 Mice
Current Alzheimer Research A SELDI-TOF-MS Study in Lacunar Stroke with Subsequent Haptoglobin Phenotyping
Current Neurovascular Research Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer's Disease: α7-nAChR Agonists in Human Clinical Trials
Current Pharmaceutical Design Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Tacrine Derivatives and Alzheimers Disease
Current Medicinal Chemistry Metabotropic Glutamate Receptors in the Control of Neuronal Activity and as Targets for Development of Anti-Epileptogenic Drugs
Current Medicinal Chemistry Ethanol and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
Medicinal Chemistry Memory Impairment is Associated with Serum Methylarginines in Older Adults
Current Alzheimer Research Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The 4-Quinolone-3-Carboxylic Acid Motif as a Multivalent Scaffold in Medicinal Chemistry
Current Medicinal Chemistry A Novel Immunotherapy for Alzheimers Disease: Antibodies against the β-Secretase Cleavage Site of APP
Current Alzheimer Research Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer’s and Parkinson’s Disease
Current Medicinal Chemistry Non-Pharmacological Approaches to the Prevention and Treatment of Alzheimer’s Disease with Respect to the Rising Treatment Costs
Current Alzheimer Research Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia
Current Neuropharmacology




